Summary of the NACI Update on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine

J Brophy1, O Baclic2, MC Tunis2 on behalf of the National Advisory Committee on Immunization (NACI)*

Abstract

Background: In Canada, pertussis is an endemic and cyclical disease, with peaks occurring at two- to five-year intervals. Although pertussis incidence varies by age group, unvaccinated or undervaccinated infants are at greatest risk of infection and associated complications. Since the last National Advisory Committee on Immunization (NACI) recommendations published in 2014, new evidence on the safety and effectiveness of tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine administration in pregnancy has become available.

Objective: To provide guidance on maternal immunization in pregnancy as a strategy to reduce disease incidence and severe outcomes (defined as hospitalization or death) from pertussis infection in infants less than 12 months of age.

Methods: The NACI reviewed evidence on the burden of disease in Canada, vaccine safety and immunogenicity and vaccine effectiveness in jurisdictions that have implemented maternal immunization programs. A total of 59 articles were identified, retrieved and included in the literature review to inform this statement.

Results: In the majority of reviewed studies, post immunization increases in antibody levels resulted in more than 90% of women achieving anti-PT levels greater than or equal to 10 IU/ml one month following immunization. In infants, maternal immunization was found to result in increased pertussis antibody concentrations. In the majority of studies, following the receipt of the fourth diphtheria, tetanus and pertussis (DTaP) dose after 15 months of age, no statistically significant differences in antibody levels and avidity were observed between infants whose mothers received Tdap in pregnancy and those whose mothers did not receive Tdap in pregnancy. No major maternal or infant safety issues, including pregnancy outcomes, were reported in the reviewed literature. Effectiveness of maternal Tdap immunization in pregnancy was estimated to be over 90% against pertussis in infants younger than two months of age, with no deaths observed among infants whose mothers received Tdap in pregnancy prior to 36 weeks of pregnancy. Maternal immunization with Tdap in pregnancy also resulted in a reduction in infant disease severity and hospitalization. Vaccine effectiveness was also reported to persist after the receipt of the first three DTaP doses, with immunization in pregnancy resulting in additional protection of up to 70% in children whose mothers received Tdap in pregnancy.

Conclusion: There is now strong evidence to support the NACI recommendation that immunization with Tdap vaccine should be offered in every pregnancy. This is ideally administered between 27 and 32 weeks of gestation but evidence also supports providing maternal Tdap over a wider range of gestational ages, from 13 weeks up to the time of delivery, in view of programmatic and unique patient considerations.

Introduction

In Canada, pertussis is an endemic and cyclical disease, with peaks occurring at two- to five-year intervals. Although pertussis incidence varies by age group, unvaccinated or under vaccinated infants are at greatest risk of infection and associated complications. Between 2006 and 2015, the average age-specific incidence rates and hospitalization rates were highest among
infants less than one year of age (71.2 and 33.6 cases per 100,000 population). Between 2006 and 2016, infants less than two months of age accounted for the largest proportion of special care unit (SCU) admissions (40.5%), followed by infants three to four months of age (21.4%).

Lack of maternal immunity is assumed to increase an infant’s susceptibility to infection, both by increasing the risk of disease in mothers (and subsequent transmission to the infant) and by providing insufficient passive protection through antibody transfer (via the placenta or via breast milk). A recently-conducted serosurvey found that the majority of pregnant women (more than 90%) in Canada had undetectable anti-pertussis toxin levels. In a 2017 survey of immunization practices in Canada, the majority of provincial and territorial governments reported logistical difficulties with implementing maternal tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine immunization programs during outbreak settings only.

Since the last National Advisory Committee on Immunization (NACI) recommendations were published in 2014, new evidence on the safety and effectiveness of Tdap administration in pregnancy has become available. In accordance with the direction that was provided by the Canadian Immunization Committee, NACI reviewed the following:

- the burden of pertussis in infants less than 12 months of age
- the safety of maternal immunization with Tdap vaccine in pregnancy
- the efficacy and effectiveness of maternal immunization with Tdap in pregnancy in preventing severe outcomes of pertussis infection in infants less than 12 months of age
- the effects of maternal Tdap immunization in pregnancy on an infant’s immunological response to the primary vaccine schedule; and
- the impact of maternal Tdap immunization in pregnancy on long term protection against pertussis in children

The objective of the Statement Update was to provide guidance on maternal immunization in pregnancy as a strategy to reduce disease incidence and severe outcomes (defined as hospitalization or death) from pertussis infection in infants younger than 12 months of age. The full update is available online (1). This article is a summary of the update’s key findings.

**Methods**

NACI reviewed evidence on the burden of disease in Canada, vaccine safety and immunogenicity and vaccine effectiveness in jurisdictions that have implemented maternal immunization programs. A total of 59 articles were identified, retrieved and included in the literature review to inform this statement. Epidemiological analysis was conducted using national surveillance data including the Canadian Notifiable Disease Surveillance System (CNDSS), the Immunization Monitoring Program Active (IMPACT) and the Canadian Institute for Health Information Discharge Abstract Database (DAD). The evidence pertaining to the following questions was reviewed and critically appraised:

- Is there a significant difference in local or systemic adverse events for the mother following immunization with Tdap vaccine in pregnancy (all stages) compared with adult immunization outside pregnancy?
- Is there a significant difference in adverse fetal and neonatal health outcomes for the baby following immunization of their mother with Tdap vaccine in pregnancy?
- Is maternal immunization in pregnancy with Tdap significantly more efficacious or effective in preventing severe disease in infants under 12 months of age compared with no maternal immunization in pregnancy?
- Is the immunogenicity of diphtheria, tetanus and pertussis (DTaP) vaccination in children born to mothers immunized with Tdap vaccine in pregnancy significantly different compared with infants born to mothers who were not immunized with Tdap vaccine in pregnancy?
- Does maternal immunization with Tdap in pregnancy significantly impact efficacy or effectiveness of DTaP vaccines in preventing related disease in children younger than four to six years of age? A detailed analysis of the literature was published in a separate NACI literature review (2). An evidence synthesis and overall summary of the literature, along with specific recommendations, were provided in the NACI Statement Update (1).

**Results**

**Immunogenicity**

In the majority of reviewed studies, post immunization increases in antibody levels resulted in more than 90% of women achieving anti-PT levels greater than or equal to 10 IU/ml at one month following immunization. While no serologic correlate of clinical protection against pertussis currently exists, anti-PT levels greater than or equal to 10 IU/ml are considered to be protective against severe disease. In infants, maternal immunization was found to result in increased pertussis antibody concentrations, with avidity increasing linearly with time to delivery. In the majority of studies, following the receipt of the fourth DTaP dose after 15 months of age, statistically significant differences in antibody levels and avidity were not observed between infants whose mothers received Tdap in pregnancy and those whose mothers did not receive Tdap in pregnancy.

**Safety and effectiveness**

No major maternal or infant safety issues, including pregnancy outcomes, were reported in the reviewed literature. Effectiveness of maternal Tdap immunization in pregnancy was estimated to be over 90% against pertussis in infants younger than two months of age, with no deaths observed among infants whose mothers received Tdap prior to 36 weeks of pregnancy. Maternal immunization with Tdap in pregnancy also resulted in a reduction in infant disease severity and hospitalization. Vaccine effectiveness was also reported to persist after the receipt of the first three DTaP doses, with immunization in pregnancy resulting in 70% lower risk of pertussis in vaccinated children whose mothers received Tdap in pregnancy.

**Recommendations**

Following the review of available evidence, NACI issued a recommendation for routine immunization with Tdap vaccine in every pregnancy. Complete details of the literature
NACI recommends that immunization with Tdap vaccine should be offered in every pregnancy, irrespective of previous Tdap immunization history (Strong NACI Recommendation). NACI concludes that there is good evidence to recommend immunization (Grade A Evidence).

Routine maternal Tdap immunization during pregnancy will provide a more robust and complete protection against pertussis in infants compared to immunization during outbreak settings only. Tdap immunization in pregnancy has been shown to protect nine of 10 infants against pertussis younger than three months of age. No significant safety issues have been detected in the currently available body of scientific literature and no increased risk of serious adverse pregnancy, maternal or infant events have been reported in countries that are routinely offering Tdap vaccine for immunization in pregnancy. Similarly, no serious adverse events have been detected in Canada through Canadian Adverse Events Following Immunization Surveillance System (CAEFIS). There is currently no indication of a clinically significant change in the priming of the immunological memory of infants exposed to higher maternally-derived antibody concentrations following Tdap vaccination in pregnancy. Given the rapid waning of maternal antibody observed in studies, vaccination should be offered in each pregnancy irrespective of immunization history or the interval between pregnancies.

NACI recommends that immunization with Tdap vaccine should ideally be provided between 27 and 32 weeks of gestation (Strong NACI Recommendation, Grade A Evidence). Evidence also supports providing maternal Tdap over a wider range of gestational ages, and NACI recommends that it may be provided from 13 weeks up to the time of delivery in view of programmatic and unique patient considerations (Discretionary NACI Recommendation, Grade A/B Evidence).

Immunization should ideally be offered at 27–32 weeks of gestation, which is supported by the strongest safety and effectiveness data. Immunization between 13 and 26 weeks of gestation may also be considered in some situations (e.g., pregnancies with an increased risk of preterm delivery) to allow for longer placental exposure to higher antibody levels and maximization of antibody transfer. While it is preferable that immunization is administered in sufficient time before birth (i.e., four weeks) to allow optimal transfer of antibodies and direct protection of the infant against pertussis, it should be considered until the end of pregnancy in women who have not yet received it, as it has the potential to provide partial protection. If Tdap immunization was provided early in pregnancy (e.g., prior to recognition of pregnancy), it is not necessary to re-immunize after 13 weeks of gestation.

Various options for timing of pertussis immunization are possible; the decision on which option is preferable may depend on the considerations itemized in Table 1, below.

**Table 1: Options and considerations for pertussis immunization during pregnancy**

<table>
<thead>
<tr>
<th>Options</th>
<th>Considerations</th>
<th>Decision points</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Immunization at 27–32 weeks of gestation</td>
<td>Safety: - Strong safety data in third trimester</td>
<td>Optimal balance between safety data, clinical opportunities, limited antibody waning potential, efficient antibody formation and placental transfer for term pregnancies. This option is supported by the strongest safety and effectiveness data of all the options, and allows enough time for the antibody response to fully develop in pregnancy. Vaccination can be paired with routine maternal visits, but may not provide protection for some preterm births.</td>
</tr>
<tr>
<td></td>
<td>Effectiveness: - Effectiveness data primarily span vaccination (27–36 weeks of gestation)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Immunogenicity: - Peak maternal anti-pertussis antibody levels are achieved approximately four weeks following vaccination</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Placental transfer of maternal antibodies is optimal in third trimester</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Feasibility or acceptability: - Could be paired with routine prenatal visit during which gestational diabetes screening is offered (24–28 weeks of gestation)</td>
<td></td>
</tr>
<tr>
<td>2. Immunization at 13–26 weeks of gestation</td>
<td>Safety: - Fewer safety data in second trimester</td>
<td>Safety data are fewer for second trimester, and effectiveness data are not stratified for immunization during second trimester. Second trimester vaccination increases clinical opportunities to offer vaccination and ensures optimal antibody formation and transfer for both term and preterm infants. For preterm deliveries, a narrow window of opportunity exists between onset of significant transplacental antibody transfer at 28 weeks and delivery.</td>
</tr>
<tr>
<td></td>
<td>Effectiveness: - Effectiveness data not stratified for immunization in second trimester (includes immunization in both second and third trimester)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Immunogenicity: - Peak maternal anti-pertussis antibody levels are achieved approximately four weeks following vaccination</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Some reports have shown greater antibody concentrations in infants following vaccination at 13–25 weeks compared with that seen following vaccination at more than or equal to 26 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Earlier vaccine administration in second trimester has been shown to result in higher antibody avidity (binding)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Feasibility or acceptability: - Could be paired with routine prenatal visits, either after detailed anatomical ultrasound is reviewed (typically done 18–22 weeks of gestation) or when gestational diabetes screening is performed (24–28 weeks of gestation)</td>
<td></td>
</tr>
<tr>
<td>3. Immunization before 13 weeks of gestation</td>
<td>Safety: - Limited safety data in first trimester</td>
<td>Safety data are limited before 13 weeks, and effectiveness data are not stratified for first trimester immunization. When given early in pregnancy antibody may wane before term delivery.</td>
</tr>
<tr>
<td></td>
<td>Effectiveness: - No effectiveness data stratified for immunization prior to 13 weeks of gestation</td>
<td></td>
</tr>
</tbody>
</table>
Table 1: Options and considerations for pertussis immunization during pregnancy (cont’d)

<table>
<thead>
<tr>
<th>Options</th>
<th>Considerations</th>
<th>Decision points</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Immunization before 13 weeks of gestation (cont’d)</td>
<td>Immunogenicity • Maternal antibodies will start to wane prior to term delivery • Placental transfer of maternal antibodies is minimal prior to third trimester Feasibility or acceptability • If vaccine is administered prior to detailed anatomical ultrasound, fetal anomalies and other first trimester pregnancy-related complications may be misattributed to the vaccine • The vaccine may not be considered acceptable by patients and clinicians in the first trimester of pregnancy</td>
<td>There is a risk of adverse events in pregnancy being misattributed to vaccination.</td>
</tr>
<tr>
<td>4. Immunization after 32 weeks of gestation</td>
<td>Safety • Strong safety data in third trimester Effectiveness • Effectiveness data primarily span vaccination (27–36 weeks of gestation) Immunogenicity • Placental transfer of maternal antibodies is optimal in third trimester • Peak maternal anti-pertussis antibody levels are achieved approximately four weeks following vaccination Feasibility or acceptability • Clinical opportunities for vaccination exist with frequent routine prenatal visits towards the end of pregnancy</td>
<td>The strongest safety and effectiveness data are from the third trimester. This option may not allow sufficient time (i.e., four weeks) for the development and transfer of maternal antibodies before delivery. Late vaccination will not provide protection for most preterm births. There may be fewer clinical opportunities to offer vaccination in late pregnancy compared with earlier vaccination.</td>
</tr>
</tbody>
</table>

### Conclusion

There is now strong evidence to support the NACI recommendation that immunization with Tdap vaccine should be offered in every pregnancy. This is ideally administered between 27 and 32 weeks of gestation but evidence also supports providing maternal Tdap over a wider range of gestational ages from 13 weeks up to the time of delivery in view of programmatic and unique patient considerations.

### Authors’ statement

This statement was prepared by the NACI Pertussis Working Group: Dr. J. Brophy (Chair), Dr. N. Brousseau, Dr. E. Castillo, Dr. N. Crowcroft, Dr. S. Deeks, Dr. I. Gemmill, Dr. S. Halperin, Dr. B. Henry, Dr. M. Naus, Dr. M. Salvadori, Dr. B. Seifert.

### Conflict of Interest

None.

### Acknowledgements

NACI acknowledges and appreciates the contribution of S. Duchesne-Belanger (Centre for Immunization and Respiratory Infectious Diseases [CIRID], Public Health Agency of Canada [PHAC]), L. Gamble (Health Library), J. Rotondo (CIRID, PHAC), and M. Saboui (CIRID, PHAC) to the statement.

NACI Members: Dr. C. Quach (Chair), Dr. W. Vaudry (Vice-Chair), Dr. N. Dayneka, Dr. P. DeWals, Dr. S. Deeks, Dr. V. Dubey, Dr. R. Harrison, Dr. M. Lavoie, Dr C. Rotstein, Dr. M. Salvadori, Dr. B. Sander, Dr. N. Sicard, Dr. R. Warrington

Former NACI Members: Dr. B. Henry, Dr. I. Gemmil, Dr. S. Marchant-Short, Dr. D. Vinh

Liaison Representatives: Dr. J. Brophy (Canadian Association for Immunization Research and Evaluation [CAIRE]), Dr. E. Castillo (Society of Obstetricians and Gynaecologists of Canada), Dr. A. Cohn (Centers for Disease Control and Prevention, United States), Ms. T. Cole (Canadian Immunization Committee), Dr. J. Emili (College of Family Physicians of Canada), Dr. K. Klein (Council of Chief Medical Officers of Health), Dr. C. Mah (Canadian Public Health Association), Dr. D. Moore (Canadian Paediatric Society), Dr. A. Pham-Huy (Association of Medical Microbiology and Infectious Disease [AMMI] Canada)

Former Liaison Representatives: Dr. J. Blake (Society of Obstetricians and Gynaecologists of Canada)

Ex-Officio Representatives: Dr. (LCdr) K. Barnes (National Defence and the Canadian Armed Forces), Ms. G. Charos (CIRID, PHAC), Dr. G. Coleman (Biologics and Genetic Therapies Directorate, Health Canada [HC]), Dr. J. Gallivan (Marketed Health Products Directorate [MHPD], HC), Ms. J. Pennock (CIRID, PHAC), Mr. G. Poliquin (National Microbiology Laboratory), Dr. T. Wong (First Nations and Inuit Health Branch, HC)

### Funding

The work of NACI is supported by the Public Health Agency of Canada.

### References
